Avaleht532523 • BOM
add
Biocon Ltd
Viimane sulgemishind
323,15 ₹
Tänane vahemik
322,45 ₹ - 332,30 ₹
Aasta vahemik
231,35 ₹ - 395,65 ₹
Turuväärtus
396,60 mld INR
Keskmine maht
170,80 tuh
P/E suhe
27,55
Dividendimäär
0,15%
Põhibörs
NSE
Börsiuudised
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
(INR) | sept 2024info | Y/Y muutus |
---|---|---|
Käive | 35,90 mld | 3,70% |
Põhitegevusega seonduv kulu | 21,42 mld | 8,03% |
Puhastulu | −160,00 mln | −112,74% |
Puhaskasumimarginaal | −0,45 | −112,40% |
Puhaskasum aktsia kohta | −0,19 | −115,53% |
EBITDA | 6,78 mld | −6,58% |
Tõhus maksumäär | 72,46% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
(INR) | sept 2024info | Y/Y muutus |
---|---|---|
Sularaha ja lühiajalised investeeringud | 26,50 mld | −30,00% |
Kogu vara | 571,28 mld | 4,67% |
Kõik kohustused | 304,08 mld | 0,36% |
Kogu omakapital | 267,20 mld | — |
Emiteeritud aktsiate arv | 1,23 mld | — |
Hinna ja väärtuse suhe P/B | 1,89 | — |
Varade tasuvus | — | — |
Kapitali tasuvus | 1,56% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
(INR) | sept 2024info | Y/Y muutus |
---|---|---|
Puhastulu | −160,00 mln | −112,74% |
Põhitegevuse rahakäive | — | — |
Investeeringute raha | — | — |
Finantseerimise raha | — | — |
Raha ja raha ekvivalentide muutus | — | — |
Tasuta rahavoog | — | — |
Teave
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Tegevjuht
Asutatud
1978
Peakontor
Veebisait
Töötajate arv
16 315